+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968783
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Multiple Sclerosis Market is entering a new phase defined by innovation, regulatory change, and dynamic shifts in therapeutic approaches. Senior executives face an increasingly intricate environment where decision-making must be agile and evidence-driven, backed by deep insights into evolving market landscapes.

Market Snapshot: Multiple Sclerosis Market Growth and Trajectory

The Multiple Sclerosis Market grew from USD 18.05 billion in 2024 to USD 19.59 billion in 2025. It is expected to continue growing at a CAGR of 8.28%, reaching USD 29.11 billion by 2030. This expansion is driven by robust innovation in biologics, precision medicine, and digital health, all contributing to a more patient-centric and collaborative ecosystem for market participants across geographies.

Scope & Segmentation

This report provides a comprehensive breakdown, ensuring actionable intelligence for product positioning and strategic planning:

  • Disease Types: Primary Progressive, Relapsing Remitting, Secondary Progressive
  • Mechanisms of Action: Fumarate Therapies, Immunomodulators (Glatiramer Acetate, Interferons), Immunosuppressants (Mitoxantrone), Monoclonal Antibodies (Alemtuzumab, Natalizumab, Ocrelizumab, Ofatumumab), Sphingosine 1 Phosphate Receptor Modulators (Fingolimod, Ozanimod, Ponesimod, Siponimod)
  • Routes of Administration: Injectable, Intravenous, Oral
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End Users: Home Care Settings, Hospitals, Specialty Clinics
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Biogen Inc., Novartis AG, Roche Holding AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Merck KGaA, Bayer AG, Pfizer Inc., Johnson & Johnson

Key Takeaways for Decision-Makers

  • Diagnostic precision, cross-functional alignment, and collaboration are central to advancing new treatment paradigms and capturing opportunities in this evolving landscape.
  • Stakeholder models are diversifying, as patient advocacy groups, regulatory bodies, and enterprise leaders jointly influence therapeutic access and innovation incentives.
  • Digital health technologies—including remote monitoring and predictive analytics—are redefining adherence and patient outcome tracking across care settings.
  • Segmentation strategies based on disease type, route of administration, and end-user dynamics help organizations tailor pipelines, value messaging, and service models with greater specificity.
  • Advanced real-world evidence platforms and artificial intelligence applications are streamlining clinical trial design, reducing attrition, and expediting regulatory approval processes.

Tariff Impact: U.S. Policy Adjustments and Their Market Effects

Recent changes in U.S. tariff structures have reshaped supply chain strategies for pharmaceutical manufacturers, impacting import duties on key active ingredients and biologics. This has prompted increased investment in domestic production, scenario-based planning for procurement, and new approaches to cost allocation with payers and providers. Stakeholders are leveraging stronger coalitions to ensure continuity and affordability amidst volatility.

Methodology & Data Sources

The research utilizes qualitative interviews with frontline clinicians, payers, and patient advocates, combined with secondary analysis from peer-reviewed literature, regulatory filings, and proprietary databases. A triangulation approach reconciles varied inputs, and an advisory panel validates key findings for alignment with real-world trends and industry best practices.

Why This Report Matters

  • Supports immediate and future commercial, product, and supply chain decisions through detailed segmentation and regional insight.
  • Guides strategic alliances and portfolio development by illuminating emerging therapy classes, evolving access models, and next-generation patient engagement tools.
  • Equips enterprise leaders to navigate regulatory and policy-driven shifts, minimizing disruptions without compromising innovation or patient access.

Conclusion

The Multiple Sclerosis Market is shaped by intersecting advances in science, policy, and care delivery. Stakeholders prepared to leverage data-driven frameworks and strategic partnerships are best positioned to capitalize on emerging opportunities while strengthening patient-centric value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased adoption of BTK inhibitors following positive phase III trial outcomes for progressive MS
5.2. Expansion of at-home telehealth services enabling remote monitoring of multiple sclerosis patients
5.3. Integration of digital biomarkers and AI algorithms in MS relapse prediction models
5.4. Rising use of S1P receptor modulators following approvals in pediatric and older MS populations
5.5. Emergence of gene therapy clinical trials targeting remyelination in aggressive multiple sclerosis forms
5.6. Surge in investment for personalized MS treatments leveraging pharmacogenomic patient profiling
5.7. Growing emphasis on real-world evidence to support reimbursement of high-cost MS therapies
5.8. Development of sustained-release neuroprotective agents aiming to slow MS disease progression
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Sclerosis Market, by Multiple Sclerosis Type
8.1. Introduction
8.2. Primary Progressive
8.3. Relapsing Remitting
8.4. Secondary Progressive
9. Multiple Sclerosis Market, by Mechanism Of Action
9.1. Introduction
9.2. Fumarate Therapies
9.3. Immunomodulators
9.3.1. Glatiramer Acetate
9.3.2. Interferons
9.4. Immunosuppressants
9.4.1. Mitoxantrone
9.5. Monoclonal Antibodies
9.5.1. Alemtuzumab
9.5.2. Natalizumab
9.5.3. Ocrelizumab
9.5.4. Ofatumumab
9.6. Sphingosine 1 Phosphate Receptor Modulators
9.6.1. Fingolimod
9.6.2. Ozanimod
9.6.3. Ponesimod
9.6.4. Siponimod
10. Multiple Sclerosis Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Intravenous
10.4. Oral
11. Multiple Sclerosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Multiple Sclerosis Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Multiple Sclerosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multiple Sclerosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multiple Sclerosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Biogen Inc.
16.3.2. Novartis AG
16.3.3. Roche Holding AG
16.3.4. Sanofi S.A.
16.3.5. Teva Pharmaceutical Industries Ltd.
16.3.6. Bristol-Myers Squibb Company
16.3.7. Merck KGaA
16.3.8. Bayer AG
16.3.9. Pfizer Inc.
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MULTIPLE SCLEROSIS MARKET: RESEARCHAI
FIGURE 26. MULTIPLE SCLEROSIS MARKET: RESEARCHSTATISTICS
FIGURE 27. MULTIPLE SCLEROSIS MARKET: RESEARCHCONTACTS
FIGURE 28. MULTIPLE SCLEROSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MITOXANTRONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MITOXANTRONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 123. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 128. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 129. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 130. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 131. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 132. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 133. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 146. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 150. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 151. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 238. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 239. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 242. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 243. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 260. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 261. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 288. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 289. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 290. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 291. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 292. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 293. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 294. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 295. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 296. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 297. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 298. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 299. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2024 (USD MILLION)
TABLE 306. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2025-2030 (USD MILLION)
TABLE 307. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 310. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 311. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 314. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 315. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILL

Samples

Loading
LOADING...

Companies Mentioned

  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.11 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Multiple Sclerosis Drugs Market Report 2025 - Product Image

Multiple Sclerosis Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030 - Product Image

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Relapsing Remitting Multiple Sclerosis Market - Product Image

Relapsing Remitting Multiple Sclerosis Market

  • Report
  • 250 Pages
  • Global
From

About the Multiple Sclerosis Drug Market

The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected. MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants. The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.